Article
Study of verteporfin therapy leads to new VIM Trial to determine effectof fluence rate, light dose
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Beacon Therapeutics exercises option to license Abeona Therapeutics’ AAV204 capsid
3 Things You Should Know About Interventional Glaucoma Comanagement
RetinalGenix Technologies and LabCorp partner on DNA/RNA/GPS Pharmaco-Genetic Mapping platform
Patient-Centered Treatment Strategies in the Management of nAMD and DME
Yale researchers identify corneal ulcer pathogens by testing tears
Health Canada approves Biocon's Yesafili, biosimilar to Eylea